Hydrogen Therapy Shows Promise for Treating Osteoporosis in Mice
- Authors
- Shunyi Lu, Jie Cao, Zhuorun Song, Fei Gong, Peng Yang, Jun Ge, Yunfei He, Zhihui Han, Guanghui Hou, Zimin Zhang, Yuqi Yang, Yun Teng, Zengli Zhang, Jun Zou, Liang Cheng, Huilin Yang
- Journal
- Nature Communications
- Year
- 2025
- DOI
- 10.1038/s41467-025-63456-5
- Study Type
- Mouse
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- China
- Health Condition
- Osteoporosis
- Body System
- Skeletal
TL;DR
A new hydrogen-releasing bone implant helps heal osteoporosis-related damage by reducing harmful inflammation and boosting bone repair.
Key Finding
A composite scaffold that releases hydrogen gas, magnesium ions, and dimethyl fumarate suppressed inflammation-driven bone loss and promoted bone tissue repair in female mice with osteoporosis.
Summary
Researchers developed a special scaffold (a porous support structure) made of gelatin, magnesium, and other compounds that slowly releases hydrogen gas into bone defects in female mice with osteoporosis. The scaffold works by reducing a type of inflammatory cell death called pyroptosis and using hydrogen's antioxidant properties to calm inflammation, while magnesium helps repair bone tissue. In tests on mice, this combination approach successfully reduced inflammation and improved bone healing.
Practical Takeaway
This early-stage research in mice suggests that combining hydrogen therapy with inflammation-blocking compounds may help treat osteoporosis, but this is a preliminary animal study using an implanted scaffold—not a form of hydrogen water that humans can drink. Much more research, including human trials, would be needed before any therapeutic claims could be made.
Abstract
The treatment of osteoporosis and related bone defects remains challenging. This study identifies pyroptosis-driven inflammation as a key disruptor of bone homeostasis. To address this, we develop a magnesium-gelatin composite microsphere scaffold (GelMa/Mg/DMF MS) that exploit pyroptosis blockade and hydrogen-mediated inflammation regulation for osteoporosis treatment. This porous microsphere scaffold is implanted into bone defects to achieve the sustained release of hydrogen gas, magnesium ions (Mg2+), and dimethyl fumarate (DMF). DMF act by activating the nuclear factor erythroid-related factor 2 to prevent osteoblast pyroptosis, and combine with the antioxidant effects of hydrogen, effectively remodel the inflammatory microenvironment and create favorable conditions for the restoration of bone homeostasis. Mg2+ further expedite bone tissue repair. These results demonstrate that the GelMa/Mg/DMF MS effectively reverse inflammatory microenvironments both in vivo and in vitro, resulting in significant tissue repair. These results suggest the combination of hydrogen therapy and pyroptosis blockade as a potential therapeutic strategy.